1.Mechanism of arrhythmias caused by autoantibodies against ?_1-adrenoceptors induced by hepatitis B virus in mice
Kun LIU ; Yuhua LIAO ; Zhaohui WANG ; Shuli LI ; Ming WANG ; Linglan ZENG ; Ming TANG
Chinese Journal of Pathophysiology 1989;0(06):-
AIM: To investigate the significance of autoantibodies against ?_1-adrenoceptors induced by hepatitis B virus in the pathogenesis of hepatitis virus myocarditis. METHODS: 30 mice were injected peritoneally with an emulsion of hepatitis B virus and complete Freund's adjuvant every three weeks. The autoantibodies were examined by ELISA, the heart and liver specimens were collected on 56 d for pathological observation and the binding of the autoantibodies to guinea pig cardiac myocytes were examined by immunofluorescence. Using the patch clamp technique, the effects of (1∶50) autoantibodies purified by octanoic acid extraction on the action potential and L type Ca~(2+) currents of guinea pig cardiac myocytes were also investigated. RESULTS: There was a good correlation between the autoantibodies and hepatitis B virus. Without pathological changes in the heart and liver specimens, 6 mice of the test group manifested bundle branch block, sinus arrest and premature ventricular beat etc, which were positive in the autoantibodies. The specific binding of the autoantibodies of the mice to guinea pig cardiac myocytes was observed. (1∶50) autoantibodies of the mice prolonged APD_(20), APD_(50), APD_(90) by 36.46%, 29.63% and 12.40%, respectively and enhanced L type Ca~(2+) currents by (49.67?16.01)%. CONCLUSIONS: Autoantibodies against ?_1-adrenoceptors of the mice induced by hepatitis B virus result in several arrhythmias, which might be mediated by the enhancement of L type Ca~(2+) currents.
2.Clinical study of pidotimod in reducing pulmonary infection in patients with lung cancer undergoing chemotherapy
Guorui SUN ; Shuli XU ; Hongying YAO ; Tao LIU ; Mozhao CHENG ; Jing LIU ; Qichao WANG ; Shuhong TANG
Chinese Journal of Postgraduates of Medicine 2021;44(5):430-433
Objective:To investigate the effect of pidotimod in reducing pulmonary infection in patients with lung cancer undergoing chemotherapy.Methods:One hundred and twenty patients with lung cancer in the Fifth People′s Hospital of Dalian City from July 2017 to July 2018 were selected. The patients were divided into control group and pidotimod group by random digits table method with 60 cases each. The patients were treated with standard two drugs chemotherapy containing platinum drug according to the pathological type, and the patients in pidotimod group were combined with pidotimod. The number of pulmonary infections during chemotherapy, number of completed scheduled chemotherapy and adverse reaction were observed. The correlation between pulmonary infection and pidotimod was analyzed by multivariate orderly Logistic regression.Results:The incidence of pulmonary infection in pidotimod group was significantly lower than that in control group: 18.33% (11/60) vs. 40.00% (24/60), and there was statistical difference ( χ2 = 6.845, P<0.01). The rate of completed scheduled chemotherapy in pidotimod group was significantly higher than that in control group: 55.00% (33/60) vs. 36.67% (22/60), and there was statistical difference ( χ2 = 4.062, P<0.05). Multivariate orderly Logistic regression analysis result showed that pidotimod could reduce the risk of pulmonary infection ( OR = 0.210, 95% CI 0.072 to 0.606, P = 0.004), and help to complete the scheduled chemotherapy ( OR = 2.323, 95% CI 1.080 to 5.003, P = 0.031). In pidotimod group, no obvious adverse reaction related to pidotimod application was detected, and chemotherapy was not affected. Conclusions:Application of pidotimod can reduce the chance of pulmonary infection in patients with lung cancer undergoing chemotherapy and help patients complete scheduled chemotherapy.
3.The SLC22A5 genetic analysis in Chinese patients with systemic primary carnitine deficiency
Pengqiang WEN ; Zhanling CHEN ; Guobing WANG ; Zhe SU ; Lisheng WAN ; Dong CUI ; Gen TANG ; Xiaohong LIU ; Shuli CHEN
Chinese Journal of Endocrinology and Metabolism 2017;33(3):208-214
Objective To investigate the clinical and biochemical metabolic features of 12 patients with systemic primary carnitine deficiency(CDSP) and to identify the SLC22A5 gene mutation types of the disease. Method The clinical and biochemical data were collected by retrospective analysis. DNA direct sequencing and multiplex ligation dependent probe amplification(MLPA)were applied for SLC22A5 gene analysis. Result Among 12 patients with CDSP, 3 cases had evident infection factors, 6 cases with convulsions, 5 cases manifested liver hypertrophy, 8 cases with hyperammonemia, and 9 cases showed myocardial damage. All CDSP patients were detected biallelic pathogenic mutation in SLC22A5 gene by direct sequencing. The gene types include IVS2+1G>T, c.3G>T(p.Met1Ile), c.760C>T(p.Arg254X), c.1400C>G(p.Ser467Cys), c.844dupc(p.Arg282fs), c.338G>A(p.Cys113Tyr), c.51C>G(p.Phe17Leu), c.659A>T(p.Glu220Val), and c.1365dupC(p.Thr456fs). c.659A>T(p.Glu220Val) and c.1365dupC(p.Thr456fs)are novel mutations. One female patient was maternal CDSP, her child had abnormal newborn screening. The allele frequency of c.760C>T(p.Arg254X) and c.1400C>G(p.Ser467Cys) were 37.5%(9/24)and 29.2%(7/24)respectively. The MLPA test results of all patients were negative. Conclusion The clinical manifestations are complex and various in patients with CDSP. Point and small InDel(insertions/deletions)mutation constitute the major alteration in SLC22A5 gene. c.1400C>G(p.Ser467Cys) might be another prevalence mutation type in Chinese CDSP patient.
4. Investigation into the expression of c-MET in patients with lung adenocarcinomaand its prognostic correlation
Jing LIU ; Shuli XU ; Hongying YAO ; Tao LIU ; Mozhao CHENG ; Shuhong TANG
Chinese Journal of Postgraduates of Medicine 2019;42(10):908-911
Objective:
To analyze the expression of c-MET and its prognostic correlation in patients with lung adenocarcinoma.
Methods:
The clinical data and pathological specimen of patients with lung adenocarcinoma in Dalian 5th People′s Hospital from January 2006 to December 2011 were retrospectively analyzed. The expression difference of c-MET between lung adenocarcinoma tissue and normal adjacent tissues was compared. The correlation of c-MET with the pathology and clinical factors was also analyzed.
Results:
A total of 82 patients were retrospective analyzed, including 82 pathological specimens of lung adenocarcinoma and 45 specimens of normal adjacent tissues. Among 53 patients with stage Ⅰ-Ⅱ lung adenocarcinoma, 31 cases had low expression of c-MET and 22 cases had high expression of c-MET. Among 29 patients with stage Ⅲ lung adenocarcinoma, 10 cases had low expression of c-MET and 19 cases had high expression of c-MET. There was a correlation between TNM stage and c-MET positive expression in lung adenocarcinoma (
5.Expression of miR-320a and CYLD in gastric cancer and its relationship with clinicopathological characteristics and prognosis
Shuli TANG ; Kuangbang HE ; Chunhui ZHANG ; Jianan CHENG ; Yanqiao ZHANG
Practical Oncology Journal 2018;32(6):538-544
Objective The aim of this study was to investigate the expression of miR-320a and cephalospermoma syndrome protein(CYLD)in patients with gastric cancer and its relationship with clinicopathological characteristics and prognosis. Methods A total of 460 patients with gastric cancer underwent tumor resection in our hospital from March 2013 to November 2014 were enrolled. Tumor tissues,non-tumor gastric mucosa tissues and normal tissues were collected. The expression of miR-320a and CYLD at levels of mRNA and protein were detected by Real-Time PCR,immunohistochemistry and Western blotting. The relationship between the expression of miR-320a and CYLD,and the clinicopathological features&prognosis of gastric cancer patients was analyzed. Results The relative expression of miR-320a and CYLD at the mRNA level in tumor tissues was(0. 37 ± 0. 09),(0. 91 ± 0. 23),and the relative expression in non-tumor tissues was(0. 86 ± 0. 15),(1. 56 ± 0. 42),respectively. The relative expression of miR-320a and CYLD mRNA in tumor tissues was significantly different from non-tumor tissues(t=60. 078,29. 113,P=0. 000),the positive ex-pression rate of CYLD protein in tumor tissues was 43. 48% when compared to 73. 91% in non-tumor tissues. The difference was statistically significant(χ2=86. 624,P=0. 003). The expression level of miR-320a was significantly associated with the diameter of the tumor and lymph node metastasis(χ2=25. 859 and 13. 742,P<0. 05). The expression of CYLD was also significantly associated with the TNM stage and degree of tumor differentiation(χ2=37. 725 and 59. 323,P<0. 05). The median survival of patients with low miR-320a expression(20. 36 months,95% CI:19. 252 ~21. 462 months) and those with high miR -320a expression(28. 29 months,95% CI:27.158~29.412 months)were statistically significant(χ2=87.967,P<0.001).The median survival of patients with CYLD negative expression(17. 70 months,95% CI:16. 599~18. 796 months)and those with CYLD positive expression(26. 74 months,95% CI:25. 474~27. 997 months)were statistically significant(χ2=109. 887,P<0. 001);The median survival of patients with the co-expressed miR-320a and CYLD was(29. 01 months,95% CI:26. 831~28. 946 months)and those with the non-co-expressed miR-320a and CYLD(17. 13 months,95% CI:17. 214~19. 568 months)were statistically significant(χ2=117. 680,P<0. 001). There showed a positive correlation between the expression of miR-320a and CYLD at mRNA level(r=0. 607,P<0. 001);miR-320a at the low expression,CYLD at the negative expression,TNM staging,lymph node metastasis and degree of tumor differen-tiation were independent risk factors for the prognosis of gastric cancer(HR=1. 939,2. 180,1. 561,1. 719,1. 608,95% CI:1. 141~3.295,1.252~3.796,1.014~2.403,1.115~2.650,1.097~2.357,respectively)(P<0.05).Conclusion The expressions of miR-320a and CYLD in tumor tissues of patients with gastric cancer is significantly decreased,which is related to the occurrence and development of diseases,and poor prognosis. It is a potential target for diagnosis and treatment of gastric cancer.
6.Ultrasonic measurement of optic nerve sheath diameter evaluation prone position ventilation intracranial pressure change of observational studies
Shuli HU ; Hao TANG ; Xuepeng FAN ; Mei LIU
The Journal of Practical Medicine 2018;34(9):1520-1523
Objective To measure the diameter of optic nerve sheath by ultrasonography to evaluate the change of intracranial pressure(ICP)in prone position ventilation,and to provide basis for prone position ventilation in patients with increased intracranial pressure (ICH). Methods A total of 58 patients with mechanical ventilation were treated with prospective clinical study from 2016.05.01 to 2017.05.01. The patients were treated with different PEEP and different positions(supine position and prone position),and detected optic nerve sheath diameter(ONSD)behind 3 mm of eye 3 mm by bedside ultrasound. The cause inducing increase of ICP was studied through the changes of ONSD and the data was analyzed by the paired t test. Results Prone position had a significant effect on patients with increased intracranial pressure. PEEP had a significant effect on MAP,Ppeak, Pplat,but had no effect on increased intracranial pressure. Conclusions Prone position ventilation significantly affect the ONSD. Therefore ,it weighs the pros and cons when patients with intracranial hypertension were received prone position ventilation.
7. Value of cardiovascular MR tissue-tracking imaging in the quantitative evaluation of myocardial strain after myocardial infarction
Qian ZOU ; Shuli ZHOU ; Tian ZHENG ; Xuepei TANG ; Shuhao LI ; Lianggeng GONG
Chinese Journal of Radiology 2018;52(8):587-592
Objective:
To investigate the application value of cardiovascular magnetic resonance tissue-tracking (CMR-TT) in the quantitative assessment of global and segmental myocardial strain after myocardial infarction.
Methods:
From June 2013 to June 2017, 45 patients with chronic myocardial infarction from the Second Affiliated Hospital of Nanchang University and eighteen normal volunteers as a control group were included in our research. All participants received CMR examination on a 3.0 T MRI scanner. Imaging protocol including FIESTA cine sequence (left ventricle short-axis planes, four chamber and two chamber long-axis planes) and late gadolinium enhancement (LGE). CMR-TT was undertaken using cvi 42 dedicated commercial software, global peak systolic circumferential, longitudinal, radial strains (GPCS, GPLS, GPRS) and segmental peak systolic circumferential, longitudinal, radial strains (PCS, PLS, PRS) in accordance with the American Heart Association's sixteen segment model were all derived. All segments were divided into five groups according to transmural extent expressed as enhanced area per segment: 0% as non-LGE segments group, 1 %-25 % as mild LGE segments group, 26%-50 % as moderate LGE segments group, 51%-75% as severe LGE segments group and >75% as complete LGE segments group. Two-independent samples
8.Efficacy evaluation of apatinib in first-line and maintenance therapy of extensive small-cell lung cancer
Jing LIU ; Shuli XU ; Hongying YAO ; Guorui SUN ; Qichao WANG ; Shuhong TANG
Chinese Journal of Postgraduates of Medicine 2022;45(7):628-632
Objective:To observe the efficacy of apatinib combined with first-line chemotherapy and maintenance therapy of only apatinib in patients with extensive small-cell lung cancer.Methods:The clinical data of 56 newly diagnosed patients with extensive small-cell lung cancer in the Fifth People′s Hospital of Dalian City from January 2018 to June 2019 were retrospectively analyzed. Among them, 27 patients (experimental group) were treated with first-line chemotherapy combined with apatinib, and 29 patients (control group) were treated with first-line chemotherapy alone. In experimental group, the expression levels of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR)-2 1 day before chemotherapy and 1 day after chemotherapy were detected by enzyme linked immunosorbent assay method. Response evaluation criteria in solid tumor (RECIST) was used to evaluate the efficacy. The occurrence of adverse reaction was recorded. The patients were followed up for 12 to 24 months, and progression-free survival and 1-year survival were recorded.Results:The objective response rate, median progression-free survival time and 1-year survival rate in experimental group were significantly higher than those in control group: 81.5% (22/27) vs. 55.2% (16/29), 10.5 months vs. 8.5 months and 81.5% (22/27) vs. 55.2% (16/29), and there were statistical differences ( P<0.05); there was no statistical difference in disease control rate between 2 groups ( P>0.05). In experimental group, the patients with complete response and partial response after chemotherapy were classified as effective subgroup (22 cases), and the patients with stationary disease and progressive disease were classified as ineffective subgroup (5 cases). There were no statistical difference in VEGF and VEGFR-2 before chemotherapy between 2 subgroups ( P>0.05). The VEGF and VEGFR-2 in effective subgroup were significantly lower than those in ineffective subgroup: (275.34 ± 16.15) ng/L vs. (330.24 ± 23.21) ng/L and (89.35 ± 4.34) ng/L vs. (112.34 ± 5.45) ng/L, and there were statistical differences ( P<0.01). There were no uncontrollable adverse reactions in 2 groups, and there was no statistical difference in the incidence of adverse reactions between 2 groups ( P>0.05). Conclusions:Application of apatinib in first-line therapy and maintenance therapy for patients with extensive small-cell lung cancer can improve clinical efficacy and survival benefit with controllable adverse reactions.
9.Clinical features and genetic analysis of a case with carnitine palmitoyltransferase 1A deficiency.
Dong CUI ; Yuhui HU ; Dan SHEN ; Gen TANG ; Min ZHANG ; Jing DUAN ; Pengqiang WEN ; Jianxiang LIAO ; Dongli MA ; Shuli CHEN
Chinese Journal of Medical Genetics 2017;34(2):228-231
OBJECTIVETo analyze the clinical and molecular features of a child with carnitine palmitoyltransferase 1A (CPT1A) deficiency.
METHODSClinical data of the child was collected. Blood acylcarnitine was determined with tandem mass spectrometry. DNA was extracted from the child and his parents. All exons and flanking regions of the CPT1A gene were analyzed by PCR and Sanger sequencing.
RESULTSAnalysis showed that the patient carried compound heterozygous mutations c.1787T>C and c.2201T>C of the CPT1A gene, which derived his father and mother, respectively. Both mutations were verified as novel through the retrieval of dbSNP, HGMD and 1000 genome databases. Bioinformatic analysis suggested that the mutations can affect protein function.
CONCLUSIONAcyl carnitine analysis has been the main method for the diagnosis of CPT1A deficiency. The c.1787T>C and c.2201T>C mutations of the CPT1A gene probably underlie the disease in this patient. Gene testing can provide important clues for genetic counseling and prenatal diagnosis.
Base Sequence ; Carnitine O-Palmitoyltransferase ; deficiency ; genetics ; Exons ; Female ; Humans ; Hypoglycemia ; enzymology ; genetics ; Infant ; Lipid Metabolism, Inborn Errors ; enzymology ; genetics ; Male ; Molecular Sequence Data ; Point Mutation ; Pregnancy